MersV1, Main, Exploration, bibRecord, 000A09

Development of Middle East Respiratory Syndrome Coronavirus vaccines - advances and challenges.

Identifieur interne : 000A09 ( Main/Exploration ); précédent : 000A08; suivant : 000A10

Development of Middle East Respiratory Syndrome Coronavirus vaccines - advances and challenges.

Auteurs : Heeyoun Cho [Corée du Sud] ; Jean-Louis Excler [Corée du Sud] ; Jerome H. Kim [Corée du Sud] ; In-Kyu Yoon [Corée du Sud]

Source :

Human vaccines & immunotherapeutics [ 2164-554X ] ; 2018.

RBID : pubmed:29048984

Descripteurs français

KwdFr :
- Coronavirus du syndrome respiratoire du Moyen-Orient (immunologie), Humains, Infections à coronavirus (), Vaccins antiviraux (immunologie), Vaccins à ADN (immunologie).
MESH :
- immunologie : Coronavirus du syndrome respiratoire du Moyen-Orient, Vaccins antiviraux, Vaccins à ADN.
- Humains, Infections à coronavirus.

English descriptors

KwdEn :
- Coronavirus Infections (prevention & control), Humans, Middle East Respiratory Syndrome Coronavirus (immunology), Vaccines, DNA (immunology), Viral Vaccines (immunology).
MESH :
- chemical , immunology : Vaccines, DNA, Viral Vaccines.
- immunology : Middle East Respiratory Syndrome Coronavirus.
- prevention & control : Coronavirus Infections.
- Humans.

Abstract

Middle East Respiratory Syndrome Coronavirus (MERS-CoV) is an emerging pathogen with the potential to pose a threat to global public health. Sporadic cases and outbreaks continue to be reported in the Middle East, and case fatality rates remain high at approximately 36% globally. No specific preventive or therapeutic countermeasures currently exist. A safe and effective vaccine could play an important role in protecting against the threat from MERS-CoV. This review discusses human vaccine candidates currently under development, and explores viral characteristics, molecular epidemiology and immunology relevant to MERS-CoV vaccine development. At present, a DNA vaccine candidate has begun a human clinical trial, while two vector-based candidates will very soon begin human trials. Protein-based vaccines are still at pre-clinical stage. Challenges to successful development include incomplete understanding of viral transmission, pathogenesis and immune response (in particular at the mucosal level), no optimal animal challenge models, lack of standardized immunological assays, and insufficient sustainable funding.

DOI: 10.1080/21645515.2017.1389362
PubMed: 29048984

Affiliations:

Corée du Sud

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Development of Middle East Respiratory Syndrome Coronavirus vaccines - advances and challenges.</title>
<author><name sortKey="Cho, Heeyoun" sort="Cho, Heeyoun" uniqKey="Cho H" first="Heeyoun" last="Cho">Heeyoun Cho</name>
<affiliation wicri:level="1"><nlm:affiliation>a Department of Clinical Development and Regulatory , International Vaccine Institute , Seoul , Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>a Department of Clinical Development and Regulatory , International Vaccine Institute , Seoul </wicri:regionArea>
<wicri:noRegion>Seoul </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Excler, Jean Louis" sort="Excler, Jean Louis" uniqKey="Excler J" first="Jean-Louis" last="Excler">Jean-Louis Excler</name>
<affiliation wicri:level="1"><nlm:affiliation>a Department of Clinical Development and Regulatory , International Vaccine Institute , Seoul , Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>a Department of Clinical Development and Regulatory , International Vaccine Institute , Seoul </wicri:regionArea>
<wicri:noRegion>Seoul </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kim, Jerome H" sort="Kim, Jerome H" uniqKey="Kim J" first="Jerome H" last="Kim">Jerome H. Kim</name>
<affiliation wicri:level="1"><nlm:affiliation>a Department of Clinical Development and Regulatory , International Vaccine Institute , Seoul , Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>a Department of Clinical Development and Regulatory , International Vaccine Institute , Seoul </wicri:regionArea>
<wicri:noRegion>Seoul </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Yoon, In Kyu" sort="Yoon, In Kyu" uniqKey="Yoon I" first="In-Kyu" last="Yoon">In-Kyu Yoon</name>
<affiliation wicri:level="1"><nlm:affiliation>a Department of Clinical Development and Regulatory , International Vaccine Institute , Seoul , Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>a Department of Clinical Development and Regulatory , International Vaccine Institute , Seoul </wicri:regionArea>
<wicri:noRegion>Seoul </wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2018">2018</date>
<idno type="RBID">pubmed:29048984</idno>
<idno type="pmid">29048984</idno>
<idno type="doi">10.1080/21645515.2017.1389362</idno>
<idno type="wicri:Area/PubMed/Corpus">000B12</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000B12</idno>
<idno type="wicri:Area/PubMed/Curation">000B12</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000B12</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000954</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000954</idno>
<idno type="wicri:Area/Ncbi/Merge">001C21</idno>
<idno type="wicri:Area/Ncbi/Curation">001C21</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001C21</idno>
<idno type="wicri:Area/Main/Merge">000A12</idno>
<idno type="wicri:Area/Main/Curation">000A09</idno>
<idno type="wicri:Area/Main/Exploration">000A09</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Development of Middle East Respiratory Syndrome Coronavirus vaccines - advances and challenges.</title>
<author><name sortKey="Cho, Heeyoun" sort="Cho, Heeyoun" uniqKey="Cho H" first="Heeyoun" last="Cho">Heeyoun Cho</name>
<affiliation wicri:level="1"><nlm:affiliation>a Department of Clinical Development and Regulatory , International Vaccine Institute , Seoul , Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>a Department of Clinical Development and Regulatory , International Vaccine Institute , Seoul </wicri:regionArea>
<wicri:noRegion>Seoul </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Excler, Jean Louis" sort="Excler, Jean Louis" uniqKey="Excler J" first="Jean-Louis" last="Excler">Jean-Louis Excler</name>
<affiliation wicri:level="1"><nlm:affiliation>a Department of Clinical Development and Regulatory , International Vaccine Institute , Seoul , Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>a Department of Clinical Development and Regulatory , International Vaccine Institute , Seoul </wicri:regionArea>
<wicri:noRegion>Seoul </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kim, Jerome H" sort="Kim, Jerome H" uniqKey="Kim J" first="Jerome H" last="Kim">Jerome H. Kim</name>
<affiliation wicri:level="1"><nlm:affiliation>a Department of Clinical Development and Regulatory , International Vaccine Institute , Seoul , Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>a Department of Clinical Development and Regulatory , International Vaccine Institute , Seoul </wicri:regionArea>
<wicri:noRegion>Seoul </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Yoon, In Kyu" sort="Yoon, In Kyu" uniqKey="Yoon I" first="In-Kyu" last="Yoon">In-Kyu Yoon</name>
<affiliation wicri:level="1"><nlm:affiliation>a Department of Clinical Development and Regulatory , International Vaccine Institute , Seoul , Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>a Department of Clinical Development and Regulatory , International Vaccine Institute , Seoul </wicri:regionArea>
<wicri:noRegion>Seoul </wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Human vaccines & immunotherapeutics</title>
<idno type="eISSN">2164-554X</idno>
<imprint><date when="2018" type="published">2018</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Coronavirus Infections (prevention & control)</term>
<term>Humans</term>
<term>Middle East Respiratory Syndrome Coronavirus (immunology)</term>
<term>Vaccines, DNA (immunology)</term>
<term>Viral Vaccines (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Coronavirus du syndrome respiratoire du Moyen-Orient (immunologie)</term>
<term>Humains</term>
<term>Infections à coronavirus ()</term>
<term>Vaccins antiviraux (immunologie)</term>
<term>Vaccins à ADN (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Vaccines, DNA</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Coronavirus du syndrome respiratoire du Moyen-Orient</term>
<term>Vaccins antiviraux</term>
<term>Vaccins à ADN</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Humains</term>
<term>Infections à coronavirus</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Middle East Respiratory Syndrome Coronavirus (MERS-CoV) is an emerging pathogen with the potential to pose a threat to global public health. Sporadic cases and outbreaks continue to be reported in the Middle East, and case fatality rates remain high at approximately 36% globally. No specific preventive or therapeutic countermeasures currently exist. A safe and effective vaccine could play an important role in protecting against the threat from MERS-CoV. This review discusses human vaccine candidates currently under development, and explores viral characteristics, molecular epidemiology and immunology relevant to MERS-CoV vaccine development. At present, a DNA vaccine candidate has begun a human clinical trial, while two vector-based candidates will very soon begin human trials. Protein-based vaccines are still at pre-clinical stage. Challenges to successful development include incomplete understanding of viral transmission, pathogenesis and immune response (in particular at the mucosal level), no optimal animal challenge models, lack of standardized immunological assays, and insufficient sustainable funding.</div>
</front>
</TEI>
<affiliations><list><country><li>Corée du Sud</li>
</country>
</list>
<tree><country name="Corée du Sud"><noRegion><name sortKey="Cho, Heeyoun" sort="Cho, Heeyoun" uniqKey="Cho H" first="Heeyoun" last="Cho">Heeyoun Cho</name>
</noRegion>
<name sortKey="Excler, Jean Louis" sort="Excler, Jean Louis" uniqKey="Excler J" first="Jean-Louis" last="Excler">Jean-Louis Excler</name>
<name sortKey="Kim, Jerome H" sort="Kim, Jerome H" uniqKey="Kim J" first="Jerome H" last="Kim">Jerome H. Kim</name>
<name sortKey="Yoon, In Kyu" sort="Yoon, In Kyu" uniqKey="Yoon I" first="In-Kyu" last="Yoon">In-Kyu Yoon</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A09 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000A09 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:29048984
   |texte=   Development of Middle East Respiratory Syndrome Coronavirus vaccines - advances and challenges.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:29048984" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a MersV1

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021

Serveur d'exploration MERS

Development of Middle East Respiratory Syndrome Coronavirus vaccines - advances and challenges.

Development of Middle East Respiratory Syndrome Coronavirus vaccines - advances and challenges.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration MERS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.